General: Patients must be assessed prior to administration of Zoledronic Acid to ensure that they are adequately hydrated. Overhydration should be avoided in patients at risk of cardiac failure. Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating therapy may be necessary. Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful function monitoring should be considered. Zoledronic Acid should not be treated with any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
